Anti-Coagulants - China

China

The Anti-Coagulants market in China is expected to witness significant growth in the coming years.
By 2024, the revenue in this market is projected to reach US$3.59bn.
This growth is expected to continue with an annual growth rate of 8.06% from 2024 to 2029.
As a result, the market volume is estimated to reach US$5.29bn by 2029.
When compared globally, it is noteworthy that United States is expected to generate the highest revenue in the Anti-Coagulants market.
In 2024 alone, the revenue United States is projected to be a staggering US$16,740.00m.
China's market for anti-coagulants is witnessing a surge in demand due to the rising prevalence of cardiovascular diseases in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The use of Anti-Coagulants in China has been on the rise in recent years, driven by factors such as an aging population and increasing incidence of cardiovascular diseases.

Customer preferences: Chinese patients are increasingly opting for Anti-Coagulants as a preventative measure against blood clots, which can lead to serious health complications such as stroke and heart attack. Additionally, many patients are choosing Anti-Coagulants over traditional blood thinners due to their convenience and ease of use.

Trends in the market: The Anti-Coagulants market in China is expected to continue growing in the coming years, driven by an aging population and increasing incidence of cardiovascular diseases. Additionally, the market is expected to see increased competition as new players enter the market and existing players expand their product offerings.

Local special circumstances: China has a large and growing population of elderly citizens, who are at a higher risk for cardiovascular diseases and blood clots. Additionally, the Chinese government has been investing heavily in healthcare infrastructure and increasing access to healthcare services, which has led to increased demand for Anti-Coagulants and other preventative medicines.

Underlying macroeconomic factors: China's rapidly growing economy and increasing middle class have led to increased healthcare spending and greater demand for high-quality medical treatments. Additionally, the Chinese government has implemented policies to encourage the development of the pharmaceutical industry and increase access to healthcare services, which has led to increased investment in research and development of new Anti-Coagulants and other medicines.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.